C reactive protein testing market to witness significant growth due to increasing elderly population and need for healthcare services during the forecast period 2023 to 2032

Market Research Future (MRFR) has published a cooked research report on the “Global C reactive protein testing Market” that contains information from 2018 to 2032. The C reactive protein testing market is estimated to register a CAGR of 6.90% during the forecast period of 2023 to 2032.

Market Highlights

The global C reactive protein testing market is accounted to register a CAGR of 6.90% during the forecast period and is estimated to reach USD 3.82 billion by 2032.

Global elderly population rise and rising healthcare service demand are anticipated to fuel market expansion. Due to the rising of chronic illnesses brought on by an aging population, more tests should be performed. Furthermore, CRP testing in healthcare institutions is driven by sedentary lifestyles and weakened immunity. Age-related increases in diagnostic testing usage are anticipated, and c-reactive protein testing demand will rise as the population ages. Comorbid conditions such as chronic diseases, osteoarthritis, and cardiac issues are more prevalent in older people.

Additionally, it lessens the responsibilities of medical professionals by doing away with demands for specimen collection and inspection from regional laboratories. Thus, over the projected period, major market players should have plenty of possibilities to participate in and contribute to the market's growth due to the development of such unique test kits. The growth of the c-reactive protein testing market is constrained by the availability of alternative disease testing methods for diseases with higher accuracy, such as the electrocardiogram (ECG), echocardiogram (ultrasound) for screening of cardiac diseases, and similar products for other diseases.

Key Players

MRFR recognizes the following companies as the key players in the global C reactive protein testing market— Randox Laboratories Limited, Merck KGAA (Millipore Sigma), Quest Diagnostics Incorporated, Abbott Laboratories, Zoetis Inc. (Abaxis Inc.), Thermo Fisher Scientific, Inc., Danaher Corporation (Beckman Coulter Inc.), Horiba, Ltd., Laboratory Corporation of America Holdings, F. Hoffmann-La Roche AG.

Segment Analysis

The global C reactive protein testing market has been segmented based on assay type and application.

On the basis of assay type, the market is segmented into enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), immunoturbidimetric assays, and others. The enzyme-linked immunosorbent assay segment was attributed to holding the largest market share in 2022 due to ELISA's numerous benefits, including the fact that it is a simple, quick, accurate, and dependable analytical technology for locating and detecting human C-reactive protein in the blood.

Based on application, the global C reactive protein testing market has been segmented into diabetes, cardiovascular disease, rheumatoid arthritis, inflammatory bowel disease, and others. The cardiovascular disease segment was expected to hold the largest market share in 2022. The primary element influencing market development is the rise in the prevalence of CVDs.

Explore In-depth Details: C Reactive Protein Testing Market Research Report

Regional Analysis

The global C reactive protein testing market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe C reactive protein testing market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The C reactive protein testing market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World C reactive protein testing market comprises Middle East, Africa, and Latin America.

The North American regional sector maintained the largest C reactive protein testing market share. The growth in cardiovascular disease incidence, more product releases, well-established companies, technical improvements, and well-established healthcare infrastructure are likely to be to blame for the dominance of this market. The increased frequency of cardiovascular illnesses in the U.S. has also resulted in the growing adoption of CRP testing.

Moreover, the Europe market has been persistently growing over the forecast period. The increase of chronic illnesses such as  ardiovascular disease ,rheumatoid arthritis, inflammatory bowel disease, the expanding market for point-of-care (POC) testing makes it possible to administer CRP testing outside of a hospital environment.

Additionally, the aging population in nations like China and Japan is growing along with the overall population. In addition, the market for c-reactive protein testing is anticipated to develop in the next years due to the widespread use of the test in hospitals and the rise in cardiovascular and malaria disorders.

Furthermore, the rest of the world's C reactive protein testing market is divided into the Middle East, Africa, and Latin America. Adopting cutting-edge diagnostic assay technology, well-established businesses, and a strong emphasis on clinical research in North America are primarily responsible for the expansion.

Key Findings of the Study

• The global C reactive protein testing market is expected to reach USD 3.82 billion by 2032, at a CAGR of 6.90% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to the widespread use of the test in hospitals and the rise in cardiovascular and malaria disorders.


• Based on application, the cardiovascular disease segment was attributed to holding the largest market in 2022, with an approximate market share of 45–65%.


• Randox Laboratories Limited, Merck KGAA (Millipore Sigma), Quest Diagnostics Incorporated, Abbott Laboratories, Zoetis Inc. (Abaxis Inc.), Thermo Fisher Scientific, Inc., Danaher Corporation (Beckman Coulter Inc.), Horiba, Ltd., Laboratory Corporation of America Holdings, F. Hoffmann-La Roche AG.